Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1983 May;80(10):3074–3077. doi: 10.1073/pnas.80.10.3074

Immunological evidence for deficiency in an activator protein for sulfatide sulfatase in a variant form of metachromatic leukodystrophy.

K Inui, M Emmett, D A Wenger
PMCID: PMC393976  PMID: 6134282

Abstract

Cultured skin fibroblasts from the patient described by Shapiro and co-workers as having a variant form of metachromatic leukodystrophy (MLD) [Shapiro, L.J., Aleck, K. A., Kaback, M.M., Itabashi, H., Desnick, R.J., Brand, N., Stephens, R.L., Fluharty, A.L. & Kihara, H. (1979) Pediatr. Res. 13, 1179-1181] were confirmed to have a partial deficiency (25-40% of controls) of arylsulfatase A activity in vitro and a severe inability to metabolize [14C]stearic acid-labeled sulfatide presented in the medium. When 150 micrograms of purified activator protein for GM1 ganglioside beta-galactosidase and sulfatide sulfatase was added in 4 ml of medium with the 14C-labeled sulfatide, correction of the sulfatide metabolism to the normal range was found. Monospecific antibodies to this activator protein were prepared in rabbits, and they were used to examine cultured cells for the presence of crossreacting material by Ouchterlony double immunodiffusion and rocket immunoelectrophoresis. Cell extracts from controls and from patients with GM1 gangliosidosis and MLD were found to have a single line of identity. By comparison to known concentrations of purified activator protein, cell extracts from controls were found to have 0.76 +/- 0.32 micrograms of activator protein (mean +/- 1 SD, n = 10) per mg of solubilized protein, whereas those from patients with type 1 GM1 gangliosidosis and late infantile MLD had 1.53 and 1.41 micrograms/mg, respectively. Cell extracts from the patient with a variant form of MLD had no visible precipitin line by Ouchterlony double immunodiffusion and only a diffuse nonspecific region of staining by rocket immunoelectrophoresis. These immunologic studies provide evidence for a deficiency in the activator protein required for normal catabolism of sulfatide in the cells from this patient and possibly provide a method for diagnosis of similar patients.

Full text

PDF
3074

Images in this article

3076Image
on p.3076
3076Image
on p.3076

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Christomanou H. Niemann-Pick disease, Type C: evidence for the deficiency of an activating factor stimulating sphingomyelin and glucocerebroside degradation. Hoppe Seylers Z Physiol Chem. 1980 Oct;361(10):1489–1502. doi: 10.1515/bchm2.1980.361.2.1489. [DOI] [PubMed] [Google Scholar]
  2. Conzelmann E., Sandhoff K. AB variant of infantile GM2 gangliosidosis: deficiency of a factor necessary for stimulation of hexosaminidase A-catalyzed degradation of ganglioside GM2 and glycolipid GA2. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3979–3983. doi: 10.1073/pnas.75.8.3979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fischer G., Jatzkewitz H. The activator of cerebroside-sulphatase. A model of the activation. Biochim Biophys Acta. 1978 Jan 27;528(1):69–76. doi: 10.1016/0005-2760(78)90053-x. [DOI] [PubMed] [Google Scholar]
  4. Hahn A. F., Gordon B. A., Gilbert J. J., Hinton G. G. The AB-variant of metachromatic leukodystrophy (postulated activator protein deficiency). Light and electron microscopic findings in a sural nerve biopsy. Acta Neuropathol. 1981;55(4):281–287. doi: 10.1007/BF00690991. [DOI] [PubMed] [Google Scholar]
  5. Hahn A. F., Gordon B. A., Hinton G. G., Gilbert J. J. A variant form of metachromatic leukodystrophy without arylsulfatase deficiency. Ann Neurol. 1982 Jul;12(1):33–36. doi: 10.1002/ana.410120106. [DOI] [PubMed] [Google Scholar]
  6. Hechtman P., Gordon B. A., Ng Ying Kin N. M. Deficiency of the hexosaminidase A activator protein in a case of GM2 gangliosidosis; variant AB. Pediatr Res. 1982 Mar;16(3):217–222. doi: 10.1203/00006450-198203000-00011. [DOI] [PubMed] [Google Scholar]
  7. Hechtman P., LeBlanc D. Purification and properties of the hexosaminidase A-activating protein from human liver. Biochem J. 1977 Dec 1;167(3):693–701. doi: 10.1042/bj1670693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ho M. W., O'Brien J. S. Gaucher's disease: deficiency of 'acid' -glucosidase and reconstitution of enzyme activity in vitro. Proc Natl Acad Sci U S A. 1971 Nov;68(11):2810–2813. doi: 10.1073/pnas.68.11.2810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Inui K., Wenger D. A. Properties of a protein activator of glycosphingolipid hydrolysis isolated from the liver of a patient with GM1 gangliosidosis, type 1. Biochem Biophys Res Commun. 1982 Mar 30;105(2):745–751. doi: 10.1016/0006-291x(82)91497-8. [DOI] [PubMed] [Google Scholar]
  10. Jatzkewitz H. Existence, localization and some properties of the activators of sphingolipid hydrolases. Adv Exp Med Biol. 1978;101:561–571. doi: 10.1007/978-1-4615-9071-2_52. [DOI] [PubMed] [Google Scholar]
  11. Kudoh T., Wenger D. A. Diagnosis of metachromatic leukodystrophy, Krabbe disease, and Farber disease after uptake of fatty acid-labeled cerebroside sulfate into cultured skin fibroblasts. J Clin Invest. 1982 Jul;70(1):89–97. doi: 10.1172/JCI110607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  13. Laurell C. B. Electroimmuno assay. Scand J Clin Lab Invest Suppl. 1972;124:21–37. doi: 10.3109/00365517209102748. [DOI] [PubMed] [Google Scholar]
  14. Li S. C., Hirabayashi Y., Li Y. T. A new variant of type-AB GM2-gangliosidosis. Biochem Biophys Res Commun. 1981 Jul 30;101(2):479–485. doi: 10.1016/0006-291x(81)91285-7. [DOI] [PubMed] [Google Scholar]
  15. Mehl E., Jatzkewitz H. Eine Cerebrosidsulfatase aus Schweineniere. Hoppe Seylers Z Physiol Chem. 1964;339(1):260–276. [PubMed] [Google Scholar]
  16. Peters S. P., Coffee C. J., Glew R. H., Lee R. E., Wenger D. A., Li S. C., Li Y. T. Isolation of heat-stable glucocerebrosidase activators from the spleens of three variants of Gaucher's disease. Arch Biochem Biophys. 1977 Sep;183(1):290–297. doi: 10.1016/0003-9861(77)90442-8. [DOI] [PubMed] [Google Scholar]
  17. Shapiro L. J., Aleck K. A., Kaback M. M., Itabashi H., Desnick R. J., Brand N., Stevens R. L., Fluharty A. L., Kihara H. Metachromatic leukodystrophy without arylsulfatase A deficiency. Pediatr Res. 1979 Oct;13(10):1179–1181. doi: 10.1203/00006450-197910000-00021. [DOI] [PubMed] [Google Scholar]
  18. Stevens R. L., Fluharty A. L., Kihara H., Kaback M. M., Shapiro L. J., Marsh B., Sandhoff K., Fischer G. Cerebroside sulfatase activator deficiency induced metachromatic leukodystrophy. Am J Hum Genet. 1981 Nov;33(6):900–906. [PMC free article] [PubMed] [Google Scholar]
  19. Wenger D. A., Sattler M., Roth S. A protein activator of galactosylceramide beta-galactosidase. Biochim Biophys Acta. 1982 Sep 14;712(3):639–649. doi: 10.1016/0005-2760(82)90293-4. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES